Advertisement

Obesity Surgery

, Volume 21, Issue 4, pp 431–439 | Cite as

A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis

  • Zobair M. YounossiEmail author
  • Sandra Page
  • Nila Rafiq
  • Aybike Birerdinc
  • Maria Stepanova
  • Noreen Hossain
  • Arian Afendy
  • Zahra Younoszai
  • Zachary Goodman
  • Ancha Baranova
Clinical Research

Abstract

Background

Patients with biopsy-proven NASH and especially those with fibrosis are at risk for progressive liver disease, emphasizing the clinical importance of developing non-invasive biomarkers for NASH and NASH-related fibrosis.

Aim

This study examines the performance of a new biomarker panel for NASH and NASH-related fibrosis with a combination of clinical and laboratory variables.

Methods

Enrolled patients had biopsy-proven NAFLD. Clinical data, laboratory data, and serum samples were collected at the time of biopsy. Fasting serum was assayed for adiponectin, resistin, glucose, M30, M65, Tissue inhibitor of metalloproteinases-1 (Timp-1), ProCollagen 3 N-terminal peptide (PIIINP), and hyaluronic acid (HA). Regression models predictive of NASH, NASH-related fibrosis, and NASH-related advanced fibrosis were designed and cross-validated.

Results

Of the 79 enrolled NAFLD patients, 40 had biopsy-proven NASH and 39 had non-NASH NAFLD. Clinical and laboratory data were from this cohort were used to develop a NAFLD Diagnostic Panel that includes three models (models for NASH, NASH-related fibrosis, and NASH-related advanced fibrosis). The model for predicting NASH includes diabetes, gender, BMI, triglycerides, M30 (apoptosis), and M65–M30 (necrosis) [AUC: 0.81, 95% CI, 0.70–0.89, 300 p value <9E 301 −06]. The NASH-related fibrosis prediction model includes the same predictors [AUC: 0.80, 95% CI 0.68–0.88, 307 p value <0.00014]. Finally, the NASH-related advanced fibrosis model includes type 2 diabetes, serum triglycerides, Timp-1, and AST [AUC: 0.81, 95% CI, 0.70–0.89; p value, 0.000062].

Conclusions

This NAFLD Diagnostic Panel based on a clinical and laboratory data has good performance characteristics and is easy to use. This biomarker panel could become useful in the management of patients with NAFLD.

Keywords

NASH Hepatic fibrosis Biomarkers 

Notes

Acknowledgments

This study has been supported by the Liver Disease Outcomes Fund of the Center for Liver Diseases at Inova Fairfax Hospital, Inova Health system. The authors acknowledge Dr. Stig Linder and Peviva, Bromma, Sweden for providing kits for M-30 and M-65.

References

  1. 1.
    Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.CrossRefPubMedGoogle Scholar
  2. 2.
    Rafiq N, Younossi ZM. Evaluation and management of non-alcoholic fatty liver disease. Clin Liver Dis. 2009;13:249–66.CrossRefPubMedGoogle Scholar
  3. 3.
    Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:746–52.CrossRefPubMedGoogle Scholar
  4. 4.
    Younossi ZM, Gramlich T, Liu Y, et al. Non- alcoholic fatty liver: assessment of variability in the pathologic interpretations. Mod Pathol. 1998;11(6):560–5.PubMedGoogle Scholar
  5. 5.
    Matteoni C, Younossi ZM, Gramlich T, et al. A non-alcoholic fatty liver disease: a spectrum of clinical and pathologic severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Rafiq N, Bai CH, Fang Y, et al. Long-term follow-up of patients with non-alcoholic fatty liver. Clini Gastro Hepatol. 2009;7(2):234–8.CrossRefGoogle Scholar
  7. 7.
    Ekstedt M et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865.CrossRefPubMedGoogle Scholar
  8. 8.
    Rosenberg WM, Voelker M, Thiel R, European Liver Fibrosis Group, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127(6):1704–13.CrossRefPubMedGoogle Scholar
  9. 9.
    Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2009;47(2):455–60.CrossRefGoogle Scholar
  11. 11.
    Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26.CrossRefPubMedGoogle Scholar
  12. 12.
    Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD J Hepatol. 2009;50:165–73.PubMedGoogle Scholar
  13. 13.
    Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18(11):1430–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27–33.CrossRefPubMedGoogle Scholar
  15. 15.
    Baranova A, Younossi ZM. The future is around the corner: non-invasive diagnosis of the progressive nonalcoholic steatohepatitis. Hepatology. 2008;47(2):373–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastro Hepatol 2009;7(11):1224–9.Google Scholar
  17. 17.
    Bondini S, Kleiner DE, Goodman Z, et al. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11:17–23.CrossRefPubMedGoogle Scholar
  18. 18.
    Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477–81.CrossRefPubMedGoogle Scholar
  19. 19.
    Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898–906.CrossRefPubMedGoogle Scholar
  20. 20.
    Miele L, Forgione A, Gasbarrini G, et al. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Transl Res. 2007;149:114–25.CrossRefPubMedGoogle Scholar
  21. 21.
    Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. 2007;25:207–18.CrossRefPubMedGoogle Scholar
  22. 22.
    Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27–33.CrossRefPubMedGoogle Scholar
  23. 23.
    Chitturi S, Farell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21(1):27–41.CrossRefPubMedGoogle Scholar
  24. 24.
    Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: human data. Clinics in Liver Disease. 2007;11(1):75–104.CrossRefPubMedGoogle Scholar
  25. 25.
    London R, George J. Pathogenesis of NASH: animal models. Clin Liver Dis. 2007;11(1):55–74.CrossRefPubMedGoogle Scholar
  26. 26.
    Nugent C, Younossi ZM. Evaluation and management of obesity-related non-alcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;14(No. 8):432–41.CrossRefGoogle Scholar
  27. 27.
    Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis. 2008;28(4):339–50.CrossRefPubMedGoogle Scholar
  28. 28.
    Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745–150.CrossRefPubMedGoogle Scholar
  29. 29.
    Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of NASH. Clin Liver Dis. 2007;11(1):37–54.CrossRefPubMedGoogle Scholar
  30. 30.
    Nguyen-Khac E, Capron D. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). Eur J Gastroenterol Hepatol. 2006;18:1321–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Ong J, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in obese patients. Obesity Surgery. 2005;15(3):310–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Baranova A, Gowder SJ, Schlauch K, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006;16:1118–25.CrossRefPubMedGoogle Scholar
  33. 33.
    Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25:760–71.CrossRefPubMedGoogle Scholar
  34. 34.
    Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic of study of the spectrum of non-alcoholic fatty liver disease. Hepatology. 2005;41(3):665–74.CrossRefGoogle Scholar
  35. 35.
    Calvert VS, Collantes R, Elariny H, et al. A systems biology approach to non alcoholic fatty liver disease pathogenesis using multiplexed cell signaling analysis. Hepatology. 2007;46(1):166–72.CrossRefPubMedGoogle Scholar
  36. 36.
    Baranova A, Liotta L, Petricoin E, et al. The role of genomics and proteomics technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11:209–20.CrossRefPubMedGoogle Scholar
  37. 37.
    Itagaki T, Shimizu I, Cheng X, et al. Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut. 2005;54:1782–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Shimizu I, Kohno N, Tamaki K, et al. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007;13:4295–305.PubMedGoogle Scholar
  39. 39.
    Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res. 2007;37:239–47.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2010

Authors and Affiliations

  • Zobair M. Younossi
    • 1
    • 2
    • 3
    Email author
  • Sandra Page
    • 2
    • 3
  • Nila Rafiq
    • 1
    • 2
  • Aybike Birerdinc
    • 2
    • 3
  • Maria Stepanova
    • 1
    • 2
  • Noreen Hossain
    • 2
  • Arian Afendy
    • 1
    • 2
  • Zahra Younoszai
    • 1
    • 2
  • Zachary Goodman
    • 1
  • Ancha Baranova
    • 1
    • 2
    • 3
  1. 1.Center for Liver DiseasesInova Fairfax HospitalFalls ChurchUSA
  2. 2.Betty and Guy Beatty Center for Integrated ResearchInova Health SystemFalls ChurchUSA
  3. 3.Center for the Study of Genomics in Liver Diseases, Molecular and Microbiology DepartmentGeorge Mason UniversityFairfaxUSA

Personalised recommendations